FDA Launches C3TI to Accelerate Clinical Trial Innovation Through Bayesian and Pragmatic Trial Pathways

For sponsors navigating drug development timelines, CDER's newly established Center for Clinical Trial Innovation (C3TI) opens structured early-engagement pathways that could reduce friction between trial design decisions and regulatory review. The center positions itself as a standing interface between drug developers and CDER staff on non-product-specific clinical trial methodology questions.

C3TI operates a Demonstration Program covering three defined areas: Bayesian statistical analysis in clinical trial settings, Selective Safety Data Collection (SSDC), and the Streamlined Trials Embedded in clinical Practice (STEP) project, which targets trials with pragmatic elements reflecting routine clinical care. Each track is designed to test and scale innovative approaches before broader adoption, giving sponsors a low-friction mechanism to engage CDER on methodology ahead of formal submissions.

The Bayesian track is particularly relevant for QA directors and biostatistics leads managing adaptive trial designs. C3TI's stated aim is to increase both the use and regulatory understanding of Bayesian methods in simpler trial settings, which has direct implications for protocol development and the statistical sections of 21 CFR Part 312 IND submissions. The SSDC project addresses a persistent tension in trial operations: how to calibrate safety data collection without compromising patient protection or regulatory acceptability.

Governance sits across CDER's Office of the Center Director, Office of Compliance, Office of Medical Policy, Office of New Drugs, and Office of Translational Sciences, a cross-office structure that signals C3TI is intended to influence review standards, not just sponsor outreach. For regulatory affairs leads, that breadth of oversight suggests guidance or policy outputs from C3TI activities could carry weight across multiple review divisions.

Sponsors can engage through a dedicated email channel and a newsletter subscription, with the Demonstration Program serving as the primary formal mechanism for early CDER interaction on innovative trial designs. A Federal Register Notice and accompanying CDER Statement have been published, establishing the program's official standing.

The degree to which C3TI's Demonstration Program outputs translate into durable guidance documents or review division alignment will be the measurable checkpoint for sponsors evaluating whether to invest in early engagement through the new center.

Source: FDA CDER via What's New: Drugs RSS Feed, 20 May 2026.